Ewing's Sarcoma Clinical Trial
Official title:
Phase 3, Open Label, Multi-centre, Randomised Controlled International Study in Ewing Sarcoma
Ewing Sarcoma
Primary objectives:
Standard Risk R1: in a randomised trial, to examine whether add-on treatment with zoledronic
acid in addition to induction and maintenance chemotherapy improves event-free survival in
patients with localised Ewing sarcoma and good histological response or with initial tumour
volume <200 mL compared to no add-on treatment.
*High Risk R2: in a randomised trial, to examine whether high-dose chemotherapy using
busulfan-melphalan with autologous stem cell reinfusion, compared with standard chemotherapy,
improves event-free survival in patients with localised Ewing sarcoma and poor histological
response or tumour volume ≥200 mL (R2loc). In patients with pulmonary metastases high dose
busulfan-melphalan chemotherapy with autologous stem cell reinfusion is randomised versus
standard chemotherapy plus whole lung irradiation (R2pulm).
Very High Risk R3: in a randomised trial, to examine whether the addition of high dose
chemotherapy using treosulfan-melphalan followed by autologous stem cell reinfusion to eight
cycles of standard adjuvant chemotherapy, compared to eight cycles of standard adjuvant
chemotherapy alone, improves event-free survival in patients with primary disseminated
disease.
*R2 accrual discontinued on December 1st 2015.
EWING 2008 is a joint protocol of European and North American Ewing sarcoma study groups. The
protocol is aimed at optimising treatment and treatment results of patients with Ewing
sarcomas. The EWING 2008 protocol is open to all patients diagnosed with Ewing sarcomas,
localised or metastatic, who are considered eligible for neoadjuvant chemotherapy. All
patients registered will receive induction chemotherapy consisting of six cycles of
vincristine, ifosfamide, doxorubicin and etoposide (VIDE). The decision regarding local
therapy must be made following the fifth cycle of induction treatment, with a preference for
surgical intervention with or without additional radiotherapy. Preoperative radiotherapy may
be considered to improve the operability of otherwise inoperable lesions. In patients with
localised disease or with pulmonary metastases, local treatment should be performed following
the 6th cycle of VIDE chemotherapy, and should be a complete tumour resection, whenever
feasible. Post-operative radiotherapy is determined by the completeness of surgery and the
histological response to chemotherapy.
Standard Risk R1 Good responders (R1) (< 10% viable tumour cells) with localised disease are
allocated to the standard risk arm and will receive a further eight cycles of chemotherapy
composed of vincristine, actinomycin D, and cyclophosphamide (VAC) (females) or ifosfamide
instead of cyclophosphamide (VAI) (males). They will be randomised to receive add-on
treatment with either fenretinide, zoledronic acid, fenretinide plus zoledronic acid, or no
add-on treatment.
High Risk R2 *Poor responders (R2) with localised disease will continue to be randomised as
in EURO-E.W.I.N.G. 99 to receive either eight cycles of VAI chemotherapy or high dose
treatment with busulfan-melphalan (R2loc).
Patients with primary pulmonary metastases are also allocated to continue to be randomised as
in EURO-E.W.I.N.G. 99 to receive either eight cycles of VAI chemotherapy or high dose
treatment with busulfan-melphalan (R2pulm).
Very High Risk R3 Patients with disseminated disease, i.e. dissemination to bone and/or other
sites and possibly additional pulmonary dissemination (R3), receive six cycles of VIDE
induction chemotherapy. Patients are then randomised to either continue with eight cycles of
vincristine, actinomycin D and cyclophosphamide (VAC) chemotherapy or high dose
treosulfan-melphalan (TreoMel) chemotherapy followed by autologous stem cell reinfusion
followed thereafter by eight cycles of VAC chemotherapy. Local therapy in R3 patients is
following VIDE induction, whenever feasible prior to high dose therapy (HDT). When long
periods of immobilisation following surgery are anticipated, e.g pelvic reconstruction,
surgery following HDT may be advisable. Depending on clinical response to induction
chemotherapy radiotherapy prior to HDT and surgery may be an option to be considered in such
patients. Any delay between VIDE and HDT for reasons of e.g. local treatment must be bridged
with VAC cycles. The total number of VAC cycles is not to exceed eight cycles.
*R2 accrual discontinued on December 1st 2015.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT01734863 -
Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients
|
Phase 3 | |
Completed |
NCT01674101 -
Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy
|
N/A | |
Completed |
NCT02736565 -
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
|
Phase 1 | |
Completed |
NCT00563680 -
QUILT-3.025: A Phase 2 Study of AMG 479 in Relapsed or Refractory Ewing's Family Tumor and Desmoplastic Small Round Cell Tumors
|
Phase 2 | |
Terminated |
NCT00038142 -
Vincristine, Doxorubicin, Cyclophosphamide and Dexrazoxane (VACdxr) in High Risk Ewing's Sarcoma Patients
|
Phase 2 | |
Completed |
NCT02890758 -
Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
|
Phase 1 | |
Completed |
NCT01583543 -
Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma
|
Phase 2 | |
Terminated |
NCT01313884 -
Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma
|
Phase 2 | |
Completed |
NCT01696669 -
Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults
|
Phase 2 | |
Completed |
NCT00004853 -
Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive Chemotherapy
|
Phase 1 | |
Terminated |
NCT00568464 -
Study on VCD/IE in the Patients With Ewing's Sarcoma Family of Tumors (ESFT)
|
Phase 2 | |
Completed |
NCT00001686 -
Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare Diseases
|
||
Completed |
NCT00492141 -
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00541411 -
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's Sarcoma
|
N/A | |
Completed |
NCT02063022 -
Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma
|
Phase 3 | |
Completed |
NCT01598454 -
Use of Racotumomab in Patients With Pediatric Tumors Expressing N-glycolylated Gangliosides
|
Phase 1 | |
Recruiting |
NCT03442465 -
Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas
|
||
Completed |
NCT02511132 -
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
|
Phase 2 | |
Completed |
NCT00923650 -
Informed Consent in Pediatric Cancer Trials
|
N/A | |
Completed |
NCT01962103 -
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
|
Phase 1/Phase 2 |